证券代码：300887 证券简称：谱尼测试 公告编号：2023-062 谱尼测试集团股份有限公司 2023 年第三次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 2、本次股东大会未涉及变更以往股东大会已通过的决议。 特别提示： 1、本次股东大会未出现否决议案的情形。 （1）现场会议时间：2023 年 8 月 22 日（星期二）下午 15:00 （2）网络投票时间：2023 年 8 月 22 日 通过深圳证券交易所交易系统进行网络投票的时间为 2023 年 8 月 22 日 9:15-9:25，9:30- 11:30 和 13:00-15:00。 通过深圳证券交易所互联网投票系统进行网络投票的时间为 2023 年 8 月 22 日上午 9:15 至下午 15:00 期间的任意时间。 一、会议召开情况 3、会议召开地点：北京市海淀区中关村环保科技示范园锦带路 66 号院 1 号楼谱尼测试大 厦公司 207 会议室 1、谱尼测试集团股份有限公司（以下简称"公司"）2023 年第三次临时股东大会通知于 2023 年 8 月 7 日在中国证监会指 ...

证券代码：300887 证券简称：谱尼测试 谱尼测试集团股份有限公司投资者关系活动记录表 编号：2023-003 | | □特定对象调研 | 分析师会议  | | --- | --- | --- | | 投资者关系活动 类别 | □媒体采访 |  业绩说明会 | | | □新闻发布会 | 路演活动  | | |  现场参观 | | | | 其他（电话会议） | | | 活动参与人员 | 详见附件 | | | 时间 | 2023 年 8 月 7 日-8 月 | 18 日 | | 地点 | 北京公司总部、上海、苏州、武汉、西安 | | | 上市公司接待 | 董事长 宋薇女士 | | | 人员姓名 | 董事会秘书 李小冬先生 | | | | IR 总监 黄子龙先生 | | 一、介绍集团情况： PONY 谱尼测试集团作为中国领先的检测行业龙头企业，创立于 2002 年，集团总部位于北京，是由国家科研院所改制而成。是拥有 30 多个大 型实验基地、150 多个专业实验室、7000 多名员工组成的网络遍布全国的 大型综合性检验认证集团。 谱尼测试集团具备 CMA、CNAS、食品复检机构、CATL、CCC 等资质 ...

证券代码：300887 证券简称：谱尼测试 公告编号：2023-061 谱尼测试集团股份有限公司 关于召开 2023 年第三次临时股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 谱尼测试集团股份有限公司（以下简称"公司"）于 2023 年 8 月 7 日在巨 潮资讯网披露了《关于召开 2023 年第三次临时股东大会的通知》。本次股东大 会将采用现场表决与网络投票相结合的方式进行，为充分保障全体股东行使表决 权，切实保护广大投资者合法权益，现将有关事项再次通知如下： 2、股东大会的召集人：公司董事会 3、会议召开的合法、合规性：公司第五届董事会第六次会议审议通过了《关 于召开公司 2023 年第三次临时股东大会的议案》，本次股东大会的召集程序符 合有关法律、行政法规、部门规章、规范性文件、深圳证券交易所业务规则和公 司章程等的规定。 4、会议召开的日期、时间： （1）现场会议时间：2023 年 8 月 22 日（星期二）下午 15:00 （2）网络投票时间：2023 年 8 月 22 日（星期二） 通过深圳证券交易所交易系统进行网络投票的时 ...

Financial Performance - The company reported a total revenue of RMB 287 million for the first half of 2023, representing a year-on-year increase of 15%[17]. - The net profit attributable to shareholders for the same period was RMB 45 million, up 20% compared to the previous year[17]. - The company's operating revenue for the reporting period was ¥1,187,184,249.88, a decrease of 29.50% compared to the same period last year[26]. - Net profit attributable to shareholders was ¥93,332,273.58, representing a 2.92% increase year-over-year[26]. - The net cash flow from operating activities improved significantly to ¥147,050,265.67, a 459.41% increase compared to the previous year[26]. - The company's revenue for the first half of 2023 was approximately ¥1.19 billion, a decrease of 29.50% compared to ¥1.68 billion in the same period last year, primarily due to a decline in medical infection-related business demand[97]. - Operating costs decreased by 39.86% to approximately ¥659.61 million, attributed to the reduction in medical infection-related business[97]. - The gross profit margin for the life sciences and health environmental sector was 41.97%, with a year-on-year decrease of 7.92%[100]. - The company reported a revenue of 1.2 billion RMB for the first half of 2023, representing a year-on-year growth of 15%[171]. - The company reported a revenue of 1.5 billion RMB for the first half of 2023, representing a year-on-year growth of 20%[186]. Market Expansion and Strategy - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 30% increase in market share by the end of 2024[17]. - The company plans to continue pursuing mergers and acquisitions that align with its strategic design to enhance business synergy and competitive advantage[85]. - The company is exploring potential mergers and acquisitions to enhance its service offerings and market presence[17]. - Market expansion plans include entering three new provinces by Q4 2023, targeting a 5% market share in these regions[171]. - The company is considering strategic acquisitions to enhance its service portfolio, with a budget of up to 200 million RMB allocated for potential deals[175]. - A strategic acquisition of a local testing firm is anticipated to enhance service capabilities and client base[187]. Research and Development - The company plans to invest 10% of its revenue into R&D for new product development and technology advancements in the next fiscal year[17]. - Research and development investment was approximately ¥102.60 million, a slight decrease of 3.60% compared to the previous year[97]. - Investment in R&D increased by 30% compared to the previous year, focusing on innovative testing technologies[187]. - The company is investing 100 million RMB in R&D for new technologies aimed at enhancing service efficiency[172]. Client and User Growth - User data indicates a growth in client base by 25%, reaching a total of 1,200 active clients by June 30, 2023[17]. - User data showed an increase in active users by 20% compared to the previous year, reaching 5 million active users[172]. - User data showed a growth of 15% in active users, reaching a total of 1.2 million users by the end of June 2023[176]. - The company reported a net profit of RMB 2.61 million from its subsidiary, Puni Testing Group Shanghai Co., Ltd., contributing significantly to overall performance[127]. Operational Efficiency and Cost Management - The management has set a performance guidance of 10-15% revenue growth for the second half of 2023[17]. - The company is focused on optimizing its management structure and improving human resource allocation to strengthen core business advantages[85]. - The company has implemented cost-cutting measures that are projected to save approximately 50 million RMB annually[171]. - The company has set a target to reduce operational costs by 15% through efficiency improvements by the end of 2023[175]. Corporate Governance and Compliance - The company emphasizes the importance of protecting shareholder and creditor rights, ensuring compliance with relevant laws and regulations[157]. - The company has not experienced any changes in its board of directors, supervisors, or senior management during the reporting period[139]. - The company has not sold any major assets or equity during the reporting period, indicating stability in its asset management[125]. - The company did not engage in any related party transactions associated with daily operations during the reporting period[195]. Social Responsibility and Sustainability - The company aims for net-zero emissions and promotes energy-saving practices among employees[160]. - The company actively participates in social welfare activities, including food safety training and public awareness campaigns, showcasing its social responsibility as a leading institution in the testing and inspection industry[162]. - The company is committed to the "rural revitalization" initiative, providing testing services valued at tens of thousands of yuan to support local agricultural development[163]. - The company integrates social responsibility into its strategic management, promoting a culture of responsibility across all business units[155]. Future Outlook - The company expects a revenue growth of 10% for the second half of 2023, projecting a total revenue of 2.4 billion RMB for the full year[170]. - Future outlook remains positive with a projected annual growth rate of 20% over the next three years[187]. - The company plans to repurchase shares to stabilize stock prices, with a total repurchase fund not exceeding 20% of the net proceeds from the latest issuance of new shares[177].

证券代码：300887 证券简称：谱尼测试 谱尼测试集团股份有限公司投资者关系活动记录表 | --- | --- | |----------------|--------------------------------------| | | 特定对象调研 □分析师会议 | | | □媒体采访 | | 投资者关系活动 | | | | □新闻发布会 | | 类别 | | | | 现场参观 | | | 其他（电话会议） | | | | | | 产；前海开源基金；汇添富；招商基金； | | | | | | 国投瑞银基金；方正富邦基金； | | | 江养老；常春藤； | | 参与单位名称 | | | 及人员姓名 | Advisors；中泰资管； | | | | | | | | | | | | | | | 自营；Point72 等 351 | | 时间 | 2023 年 4 月 20 日-5 月 | | 地点 | | | | 董事长 宋薇女士 | | 上市公司接待 | | | | 董事会秘书 李小冬先生 | | 人员姓名 | | | | IR 总监 黄子龙先生 | 一、介绍集团基本情况： 投资者关系活动 2002 年，谱 ...

Financial Performance - The company's operating revenue for 2022 was ¥3,762,085,106.93, representing an increase of 87.48% compared to ¥2,006,685,260.63 in 2021[19]. - Net profit attributable to shareholders was ¥320,802,983.23, a growth of 45.63% from ¥220,287,079.61 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was ¥273,926,063.19, up 44.01% from ¥190,215,074.58 in 2021[19]. - Cash flow from operating activities reached ¥622,992,688.67, a significant increase of 1,217.69% compared to ¥47,279,304.81 in 2021[19]. - Total assets at the end of 2022 amounted to ¥4,579,931,494.76, a 64.71% increase from ¥2,780,683,964.60 at the end of 2021[19]. - The company's basic earnings per share rose to ¥1.1585, reflecting a 29.59% increase from ¥0.8940 in 2021[19]. - The weighted average return on equity was 10.46%, down from 11.53% in the previous year[19]. - The total revenue for 2022 reached ¥3,762,085,106.93, representing an 87.48% increase compared to ¥2,006,685,260.63 in 2021[103]. - Revenue from the life sciences and health sector was ¥3,235,014,159.47, accounting for 85.99% of total revenue, with a year-on-year growth of 87.69%[103]. Profit Distribution and Shareholder Information - The company reported a profit distribution plan of 7 RMB per 10 shares (including tax) and a capital reserve conversion of 9 shares for every 10 shares[4]. - The total number of shares used as the basis for the profit distribution is 287,013,456 shares[4]. - The company has a dedicated investor relations email: IR@ponytest.com for inquiries[16]. - The company’s stock code is 300887, listed under the name Pony Testing[15]. Risk Management and Compliance - The company emphasizes the importance of rational investment and risk awareness in its forward-looking statements[4]. - The management discussion section outlines potential risk factors and countermeasures for future development[4]. - The company is committed to ensuring the accuracy and completeness of its financial reports, as stated by its management[4]. - The company does not report any significant differences between financial data disclosed under international and Chinese accounting standards[22][23]. Operational and Market Presence - The company has over 8,000 employees and operates more than 30 large testing bases and over 150 specialized laboratories nationwide, providing comprehensive quality infrastructure services[41]. - The company has been recognized and authorized by multiple national ministries, with testing reports acknowledged in over 100 countries and regions[39]. - The company is a leader in the Chinese testing industry, established in 2002, and has developed a comprehensive one-stop testing service system covering various fields[37]. - The company is actively involved in major national events, having completed critical testing tasks for the 2022 Winter Olympics and other significant occasions[38]. - The company is focused on expanding its market presence and developing new technologies to meet the growing demand for quality assurance in various sectors[34]. Research and Development - The company has a strong research and development team, accounting for 14.07% of its total workforce[84]. - R&D investment reached approximately ¥277.65 million in 2022, which is 7.38% of the total revenue[119]. - The number of R&D personnel increased to 1,180 in 2022, representing a growth of 24.47% compared to 2021[119]. - The company is committed to developing new technologies for the rapid detection of foodborne pathogens, ensuring public health safety[115]. Acquisitions and Investments - The company successfully acquired Shenzhen Tongce Testing Technology Co., Ltd., enhancing its capabilities in the medical measurement field[96]. - The acquisition of Boya Shengkang Medical laid the foundation for the company's in vitro diagnostic reagent R&D and production[90]. - The company raised a net amount of 1.227 billion CNY through a private placement of shares approved by the China Securities Regulatory Commission[89]. - The company has ongoing major non-equity investments, with specific details to be disclosed in future reports[135]. Governance and Compliance - The company has developed a comprehensive governance structure, including various committees to enhance decision-making processes[182]. - The board of directors includes more than one-third independent directors, ensuring diverse oversight[185]. - The company has established a transparent performance evaluation and incentive mechanism for senior management, ensuring fairness[189]. - The company adheres to strict information disclosure practices, ensuring timely and accurate communication with shareholders through various channels, including designated newspapers and online platforms[191]. Future Outlook - Future outlook indicates a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[179]. - The company has set a performance guidance of $200 million in net income for the next fiscal year, reflecting a 20% increase from the previous year[179]. - The company plans to implement cost-cutting measures that are expected to save approximately $10 million annually[179]. - The company aims to strengthen its national sales network and continue to pursue opportunities for industrial integration and business expansion[96].

Financial Performance - The company's operating revenue for 2022 was ¥3,762,085,106.93, representing an increase of 87.48% compared to ¥2,006,685,260.63 in 2021[19]. - Net profit attributable to shareholders was ¥320,802,983.23, a 45.63% increase from ¥220,287,079.61 in the previous year[19]. - The net cash flow from operating activities reached ¥622,992,688.67, a significant increase of 1,217.69% compared to ¥47,279,304.81 in 2021[19]. - Basic earnings per share decreased by 27.66% to ¥0.8312 from ¥1.1490 in 2021[19]. - Total assets at the end of 2022 were ¥4,579,931,494.76, up 64.71% from ¥2,780,683,964.60 at the end of 2021[19]. - The company reported a weighted average return on equity of 10.46%, down from 11.53% in the previous year[19]. - Total revenue for 2022 reached ¥3,762,085,106.93, an increase of 87.48% compared to ¥2,006,685,260.63 in 2021[101]. - Revenue from the life sciences and health sector was ¥3,235,014,159.47, accounting for 85.99% of total revenue, with a year-on-year growth of 87.69%[101]. - Gross profit margin for the technical services industry decreased to 35.55% in 2022 from 46.16% in 2021, reflecting a decline of 10.61%[103]. Investment and Capital Management - The company raised a net amount of 1.227 billion CNY through a private placement of shares approved by the China Securities Regulatory Commission[87]. - The company issued new shares, resulting in an increase in share capital from ¥137,020,570.00 to ¥287,013,456.00, a rise of 109.73%[124]. - The total investment amount for the reporting period was ¥233,506,732.56, representing a 213.73% increase compared to the previous year's investment of ¥74,430,064.70[128]. - The company has ongoing significant non-equity investments, with a total investment of ¥179,206,732.56 and a cumulative amount of ¥227,930,914.73[132]. - The company has completed significant equity investments, with a total investment amount of ¥49,000,000.00 in a testing service company, holding a 70% stake[130]. - The company has not engaged in any securities or derivative investments during the reporting period[133][134]. - The company has established a comprehensive testing group centered in Beijing, consisting of over 30 large experimental bases and more than 150 specialized laboratories nationwide, to meet the one-stop quality infrastructure service needs of clients[154]. Research and Development - The company has over 8,000 employees and operates more than 30 large testing bases and over 150 specialized laboratories across the country[42]. - The company has obtained over 380 authorized patents and more than 150 software copyrights, participating in the revision of nearly 100 international, national, and industry standards[82]. - The number of R&D personnel increased to 1,180 in 2022, a growth of 24.47% compared to 948 in 2021[117]. - R&D investment reached approximately ¥277.65 million in 2022, representing 7.38% of total revenue, slightly down from 7.48% in 2021[117]. - The company is focusing on the development of new energy vehicle harness connectors, aiming to enhance testing capabilities and reduce safety risks associated with overheating, which is critical for the automotive industry[112]. - The company is developing new testing methods for detecting 4,4'-dichlorobenzene in electronic and chemical products to meet EU REACH regulations[116]. - The company is committed to improving its brand image and competitive strength through enhanced detection capabilities and brand promotion efforts[162]. Market Expansion and Strategy - The company is focused on expanding its market presence and enhancing its service offerings in response to growing demand for health and environmental safety[13]. - The company plans to continue expanding its market presence and enhancing its service capabilities in response to industry growth trends[30]. - The company aims to enhance its profitability by leveraging its technical advantages and broadening its market scope through these new projects[114]. - The company intends to increase its overseas market development efforts while establishing a nationwide sales network to provide one-stop testing services[167]. - The company will strengthen its national sales network and explore rapid laboratory expansion, particularly in regions such as South China, Central China, Southwest China, and Northwest China[167]. Governance and Compliance - The governance structure includes a board of directors, supervisory board, and independent directors, ensuring independent operation and decision-making[180]. - The company has established a transparent performance evaluation and incentive mechanism for senior management, ensuring fairness in appointments[185]. - The company has implemented various regulatory documents to enhance governance, including rules for shareholder meetings and board operations[178]. - The company maintains independence from its controlling shareholders in terms of assets, personnel, finance, and operations, ensuring a complete and independent business system[190]. - The company has established a clear management structure with responsibilities defined for the general manager and senior management, ensuring compliance with board resolutions[186]. Risk Management - The company emphasizes the importance of rational investment and risk awareness in its forward-looking statements[4]. - The management discusses potential future risks and countermeasures in the section on future development outlook[4]. - The company faces risks related to brand reputation, market competition, policy changes, and operational performance fluctuations, which could impact its business[168][169][171]. Social Responsibility - The company engaged in social responsibility initiatives, including food safety inspections for 356 small food workshops across multiple cities[99]. - The company has established partnerships for carbon credit standards and participated in rural revitalization initiatives[98]. - The company is committed to contributing to China's carbon peak by 2030 and carbon neutrality by 2060 through scientific and practical services[52].

Financial Performance - The company's revenue for Q1 2023 was ¥525,497,117.51, a decrease of 1.50% compared to ¥533,503,557.47 in the same period last year[5] - Net profit attributable to shareholders increased by 68.08% to ¥9,263,189.46 from ¥5,511,208.06 year-on-year[5] - Total operating revenue for Q1 2023 was CNY 525,497,117.51, a decrease of 1.88% from CNY 533,503,557.47 in Q1 2022[22] - Net profit for Q1 2023 reached CNY 9,283,846.83, an increase of 68.5% compared to CNY 5,511,208.06 in Q1 2022[24] - Operating profit for the period was CNY 14,445,749.74, up from CNY 12,681,195.66 in the previous year, reflecting a growth of 13.9%[24] - Total comprehensive income for the period was CNY 9,296,493.91, compared to CNY 5,579,318.07 in Q1 2022, an increase of 66.5%[25] Cash Flow - The net cash flow from operating activities improved significantly to ¥33,250,363.92, a 144.18% increase from a negative cash flow of ¥75,269,395.38 in the previous year[5] - The cash inflow from operating activities increased by 41.28% to ¥698,051,564.48 compared to ¥494,088,097.56 in the same period last year[10] - The net cash flow from investment activities was ¥129,987,377.79, a turnaround from a negative cash flow of ¥94,853,706.42 in the previous year[11] - The company experienced a 95.68% decrease in cash inflow from financing activities, totaling ¥60,310,116.98 compared to ¥1,395,840,401.81 in the same period last year[11] - The cash and cash equivalents decreased by 85.90% to ¥156,942,530.82 from ¥1,113,402,347.78 in the previous year[11] - The cash outflow from operating activities was CNY 664,801,200.56, compared to CNY 569,357,492.94 in the previous year, indicating an increase of 16.7%[26] - The net cash flow from operating activities was CNY 33,250,363.92, a decrease of CNY 75,269,395.38 compared to the previous period[27] - The net cash flow from investing activities was CNY 129,987,377.79, an increase from a negative cash flow of CNY 94,853,706.42 in the previous period[27] - Total cash inflow from financing activities was CNY 60,310,116.98, compared to CNY 1,395,840,401.81 in the previous period[27] - The net cash flow from financing activities was negative at CNY -6,295,161.19, a significant decrease from CNY 1,283,532,979.46 in the previous period[27] - The net increase in cash and cash equivalents was CNY 156,942,530.82, compared to CNY 1,113,402,347.78 in the previous period[27] - The ending balance of cash and cash equivalents was CNY 900,296,214.14, down from CNY 1,614,175,898.71 in the previous period[27] - The company received CNY 1,086,000,000.00 from cash recovered from investments[27] - Cash paid for the acquisition of fixed assets, intangible assets, and other long-term assets was CNY 91,884,112.79[27] - Cash received from borrowings was CNY 37,000,000.00, compared to CNY 158,177,000.37 in the previous period[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 8,571[12] - The largest shareholder, Song Wei, holds 44.85% of the shares, totaling 128,737,800 shares[12] - The second-largest shareholder, Li Yanggu, holds 11.60% of the shares, totaling 33,291,000 shares[12] - The top ten shareholders collectively hold significant stakes, with the first three shareholders accounting for over 60% of the total shares[12] - The company has a total of 0 preferred shareholders with voting rights restored[14] - The report indicates that there are no shares under pledge, marking a stable financial position for the major shareholders[12] - The company has a total of 7,086,893 shares held by Hong Kong Central Clearing Limited, representing 2.47% of the total shares[12] - The report highlights that Song Wei has controlling stakes in two investment partnerships, further consolidating her influence in the company[13] - The company has not disclosed any relationships or concerted actions among the top ten shareholders beyond the known familial ties[13] - The report does not indicate any changes in restricted shares for the period, suggesting stability in shareholder equity[14] Asset Management - Total assets at the end of Q1 2023 were ¥4,468,759,733.86, down 2.43% from ¥4,579,931,494.76 at the end of the previous year[5] - The total assets decreased from CNY 4,579,931,494.76 at the beginning of the year to CNY 4,468,759,733.86 at the end of Q1 2023[20] - The company’s accounts receivable decreased from CNY 1,086,707,485.55 to CNY 969,880,833.18, a reduction of approximately 10.8%[18] - The company’s inventory increased slightly from CNY 42,094,786.94 to CNY 42,487,819.25, reflecting a growth of about 0.9%[20] - The company’s fixed assets increased slightly from CNY 1,085,040,234.39 to CNY 1,094,257,776.79, indicating a growth of about 0.2%[20] - The company’s total current liabilities decreased from CNY 99,400,000.00 to CNY 86,760,002.63, a decline of approximately 12.9%[20] - Total liabilities decreased to CNY 899,107,761.18 from CNY 1,028,704,755.20, a reduction of approximately 12.6%[22] - The company's total equity increased to CNY 3,569,651,972.68 from CNY 3,551,226,739.56, reflecting a growth of 0.5%[22] Business Operations - The company reported a stable overall business revenue in Q1 2023 despite fluctuations in the medical business segment[17] - The company successfully acquired Hubei Zhongjia Pharmaceutical Co., enhancing its raw material drug GMP production capabilities[17] - The company aims to enhance group management and improve production efficiency to increase per capita output value[17] - Research and development expenses increased to CNY 52,584,381.52, compared to CNY 44,169,647.67 in the same period last year, marking a rise of 18.9%[22] Audit Information - The first quarter report was not audited[28]

谱尼测试集团股份有限公司 关于举行 2022 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 谱尼测试集团股份有限公司(以下简称"公司") 将于 2023 年 5 月 8 日(星期一) 15： 00-17：00 在全景网举行 2022 年度业绩说明会。本次业绩说明会将采用网络远程方式举行， 投资者可登录全景网"投资者关系互动平台"(https://ir.p5w.net/ )参与本次说明会。 出席本次业绩说明会的人员有：公司董事长宋薇女士，总经理张英杰先生、董事会秘书 李小冬先生。 证券代码： 300887 证券简称：谱尼测试 公告编号： 2023-037 欢迎广大投资者积极参与！ 特此公告。 谱尼测试集团股份有限公司 董 事 会 2023 年 4 月 19 日 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提前向投资者 公 开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 5 日(星期五) 17 ：00 前访问 http://ir.p5w.net/zj/ ，或扫描下方二维码，进入问题征集专题 ...

Financial Performance - The company achieved a revenue of 312 million CNY in Q1 2021, up from 172 million CNY in the same period last year, representing a year-on-year growth of 81.4% [1] - The net profit attributable to shareholders increased by 3.8% compared to the previous year [1] - The gross profit margin for Q1 2021 was 31.35%, showing a stable slight increase compared to last year [2] Seasonal Trends - The company's sales revenue exhibits a seasonal trend, with higher growth in the second half of the year, particularly due to government procurement and agricultural product testing [2] Workforce and Growth - The company currently employs 6,700 people, an increase of 143 individuals from the end of 2020, reflecting a growth rate of 2.18% [2] - The company emphasizes productivity per employee and has effective personnel control measures in place [2] Carbon Verification and Future Plans - The company has over ten years of experience in carbon verification and is a member of the "Carbon Peak and Carbon Neutrality" working group [2] - It has conducted annual greenhouse gas emission verifications for over 450 key enterprises across multiple provinces [3] - Future plans include strengthening the theoretical foundation for carbon peak and neutrality, ensuring high-quality and efficient completion of carbon emission projects [2] Expansion and Acquisitions - The company is in the process of establishing self-built laboratories in Zhengzhou and Shandong, with an investment of 532,351,00 CNY for the Zhengzhou facility and 150 million CNY for the Shandong headquarters [3] - In Q1 2021, the company acquired three medical testing companies, integrating their business systems and marketing networks [3]